title: Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder.
abstract: Lysosomal storage disorders are collectively important because they cause significant morbidity and mortality. Patients can present with severe symptoms that include somatic tissue and bone pathology, developmental delay and neurological impairment. Enzyme-replacement therapy has been developed as a treatment strategy for patients with a lysosomal storage disorder, and for many of these disorders this treatment is either in clinical trial or clinical practice. One major complication arising from enzyme infusion into patients with a lysosomal storage disorder is an immune response to the replacement protein. From clinical trials, it is clear that there is considerable variability in the level of immune response to enzyme-replacement therapy, dependent upon the replacement protein being infused and the individual patient. Hypersensitivity reactions, neutralizing antibodies to the replacement protein and altered enzyme targeting or turnover are potential concerns for patients exhibiting an immune response to enzyme-replacement therapy. The relative occurrence and significance of these issues have been appraised.
authors.affiliation: The Lysosomal Diseases Research Unit, Department of Chemical Pathology, Women's and Children's Hospital, North Adelaide, SA 5006, Australia. douglas.brooks@adelaide.edu.au
authors.forename: Doug A
authors.initials: DA
authors.lastname: Brooks
authors.forename: Revecca
authors.initials: R
authors.lastname: Kakavanos
authors.forename: John J
authors.initials: JJ
authors.lastname: Hopwood
mesh_terms: D000818:Animals; D000906:Antibodies / Q000009:adverse effects* / Q000276:immunology*; D005962:Glucosylceramidase / Q000276:immunology / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006023:Glycoproteins / Q000276:immunology / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006026:Glycoside Hydrolases / Q000276:immunology / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D016464:Lysosomal Storage Diseases / Q000201:enzymology / Q000276:immunology* / Q000628:therapy*
chemical_list: D000906:Antibodies; D006023:Glycoproteins; C018322:IDS protein, human; D006026:Glycoside Hydrolases; D005962:Glucosylceramidase; C090568:imiglucerase